Metagenomic Deep Sequencing (MDS) for Uveitis

Phase-Based Progress Estimates
University of California San Francisco (UCSF), San Francisco, CAUveitis+1 MoreMetagenomic Deep Sequencing (MDS) - Device
All Sexes
What conditions do you have?

Study Summary

This trial is designed to compare the effectiveness of a new deep sequencing test for intraocular infections versus the current standard of care test. Patients who receive the new test will be compared to those who do not to see if there are improved outcomes.

Eligible Conditions
  • Uveitis
  • Infectious Diseases

Treatment Effectiveness

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: 4-week after randomization

4-week after randomization
Appropriate therapy
Clinical improvement
Infection status
Patient quality of life
Provider certainty of belief
Provider quality of care

Trial Safety

Trial Design

2 Treatment Groups

Standard of Care
1 of 2
1 of 2

Active Control

Experimental Treatment

100 Total Participants · 2 Treatment Groups

Primary Treatment: Metagenomic Deep Sequencing (MDS) · No Placebo Group · N/A

Experimental Group · 1 Intervention: Metagenomic Deep Sequencing (MDS) · Intervention Types: Device
Standard of Care
ActiveComparator Group · 1 Intervention: Standard of Care (SOC) · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 4-week after randomization

Who is running the clinical trial?

University of California, DavisOTHER
855 Previous Clinical Trials
5,025,223 Total Patients Enrolled
1 Trials studying Uveitis
118 Patients Enrolled for Uveitis
University of California, San FranciscoLead Sponsor
2,313 Previous Clinical Trials
11,758,268 Total Patients Enrolled
5 Trials studying Uveitis
411 Patients Enrolled for Uveitis
University of California, Los AngelesOTHER
1,423 Previous Clinical Trials
6,773,514 Total Patients Enrolled
University of UtahOTHER
1,009 Previous Clinical Trials
1,787,488 Total Patients Enrolled
1 Trials studying Uveitis
University of NebraskaOTHER
491 Previous Clinical Trials
1,149,370 Total Patients Enrolled
3 Trials studying Uveitis
36 Patients Enrolled for Uveitis
Thuy Doan, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco
3 Previous Clinical Trials
411 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have an eye condition that is believed to be caused by an infection and affects the front, middle, or back part of the eye.
You have an issue that affects either one or both sides of your body.

Frequently Asked Questions

Are there still openings to participate in this experiment?

"Affirmative. According to the database, this experiment is currently seeking participants and was originally posted on June 6th 2022 with updates occuring as recently as July 5th 2022. The study requires 100 people from a single medical facility for enrolment purposes." - Anonymous Online Contributor

Unverified Answer

What does this clinical experiment hope to demonstrate?

"This medical trial, evaluated over 4 weeks after randomisation, aims to evaluate clinical improvement. Secondary objectives include measuring infection status with latent class analysis and traditional tests; calculating provider quality of care through the World Health Organization Quality of Life Abbreviated Questionnaire; as well as capturing a provider's certainty on whether or not a patient has an infection (on a continuous scale from 0-100%)." - Anonymous Online Contributor

Unverified Answer

What is the current capacity to enroll participants for this medical experiment?

"Affirmative, the information hosted on verifies that this medical trial is currently recruiting. Its first posting was June 6th 2022 and its most recent edit occurred July 5th 2022; 100 patients are needed from a single site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.